$157 Million is the total value of CAXTON CORP's 3 reported holdings in Q4 2013. The portfolio turnover from Q3 2013 to Q4 2013 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SNTA | Buy | SYNTA PHARMACEUTICALS CORP | $150,057,000 | +0.6% | 28,641,849 | +21.2% | 95.29% | -4.6% |
| CPXX | New | CELATOR PHARMACEUTICALS INC | $7,301,000 | – | 2,246,469 | +100.0% | 4.64% | – |
| HALL | Sell | HALLMARK FINL SVCS INC EC | $119,000 | -38.7% | 13,445 | -38.7% | 0.08% | -41.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MOLECULAR TEMPLATES INC | 24 | Q2 2023 | 30.7% |
| STRONGBRIDGE BIOPHARMA PLC | 22 | Q3 2021 | 73.1% |
| GARRISON CAP INC | 18 | Q3 2020 | 9.9% |
| BERKSHIRE HATHAWAY INC DEL | 17 | Q3 2019 | 5.8% |
| EIGER BIOPHARMACEUTICALS INC | 17 | Q3 2022 | 1.7% |
| AGILE THERAPEUTICS INC | 16 | Q1 2018 | 55.5% |
| KALA PHARNACEUTICALS INC | 16 | Q4 2021 | 17.6% |
| CM FIN INC | 16 | Q1 2019 | 7.8% |
| SYNTA PHARMACEUTICALS CORP | 15 | Q2 2016 | 99.9% |
| CTI BIOPHARMA CORP | 14 | Q4 2021 | 8.7% |
View CAXTON CORP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Addex Therapeutics Ltd. | February 14, 2023 | 718,849 | 0.9% |
| Cardiff Oncology, Inc. | February 14, 2023 | 983,607 | 2.2% |
| Rezolute, Inc. | February 14, 2023 | 1,860,518 | 5.0% |
| Xeris Biopharma Holdings, Inc. | February 14, 2023 | 5,973,324 | 4.4% |
| CTI BIOPHARMA CORP | February 14, 2022 | 2,239,300 | 2.3% |
| Sierra Oncology, Inc. | February 14, 2022 | 1,119,322 | 7.0% |
| Strongbridge Biopharma plcSold out | January 05, 2022 | 0 | 0.0% |
| SUNESIS PHARMACEUTICALS INCSold out | February 16, 2021 | 0 | 0.0% |
| Alcentra Capital Corp | February 14, 2020 | 1,005,000 | 7.8% |
| Garrison Capital Inc. | February 14, 2020 | 1,223,096 | 7.6% |
View CAXTON CORP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
View CAXTON CORP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.